Skip to main content
Quest Diagnostics Home

Type 1 diabetes

Harness the insights you need to identify and treat type 1 diabetes

The Zinc Transporter 8 (ZnT8) Antibody Test helps assess the risk of type 1 diabetes. It can be used alone or in combination with other antibody tests, such as the Glutamic Acid Decarboxylase-65 (GAD-65), Insulinoma Antigen-2 (IA-2), and Insulin Antibody Tests.

In symptomatic patients, the presence of one or more of these antibodies confirms a diagnosis of type 1 diabetes.1 In asymptomatic patients, the presence of one or more of the antibodies may predict the development of type 1 diabetes.1

Roughly 65 to 80% of children with recently diagnosed type 1 diabetes2,3 and 20 to 40% of adults with type 1 diabetes have antibodies to ZnT8.3,4

When to use the ZnT8 Antibody Test

  • In individuals with diabetes of uncertain etiology
  • In obese individuals with acute-onset diabetes with ketoacidosis
  • In lean individuals with nonketotic diabetes
  • In individuals at high risk of developing type 1 diabetes (eg, those with a first-degree relative with type 1 diabetes) in the context of a clinical research study1

When the ZnT8 Antibody Test is used in conjunction with tests for other autoantibodies (GAD-65, IA-2, insulin), diagnostic sensitivity for type 1 diabetes is improved.2,4,5

Type 1 diabetes tests

ZnT8 Antibody Test
View All Tests

This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.


References
 

  1. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(suppl 1):S8-S16. doi:10.2337/dc15-S005
  2. Andersson C, Vaziri-Sani F, Delli AJ, et al. Triple specificity of ZnT8 autoantibodies in relationship to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes. Pediatr Diabetes. 2013;14(2):97-105. doi:10.1111/j.1399-5448.2012.00916.x
  3. Vaziri-Sani F, Oak S, Radtke J, et al. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity. 2010;43(8):598-606. doi:10.3109/0891693090355592
  4. Kawasaki E, Nakamura K, Kuriya G, et al. Differences in humoral autoreactivity to zinc transporter 8 between childhood- and adult-onset type 1 diabetes in Japanese patients. Clin Immunol. 2011;138(2):146-153. doi:10.1016/j.clim.2010.10.007
  5. Petruzelkova L, Ananieva-Jordanova R, Vcelakova J, et al. The dynamic changes of zinc transporter 8 autoantibodies in Czech children from the onset of type 1 diabetes mellitus. Diabet Med. 2014;31(2):165-171. doi:10.1111/dme.12308

During the COVID-19 health crisis, fast action and trusted information matter more than ever.

Find out what's happening

Learn More

Diabetes & prediabetes

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.